Who are in the management team of UTI AMC?

As of March 2022, the management team of UTI AMC includes key members such as IMTAIYAZUR RAHMAN (Managing Director), D K Mehrotra (Chairman & Independent Director), and several independent directors. The team oversees the company's operations and governance.

As of March 2022, the management team of UTI AMC includes the following individuals:<BR><BR>1. **IMTAIYAZUR RAHMAN** - Managing Director<BR>2. **Flemming Madsen** - Director<BR>3. **Narasimhan Seshadri** - Independent Director<BR>4. **Deepak Kumar Chatterjee** - Independent Director<BR>5. **Dipali H Sheth** - Independent Director<BR>6. **Edward Cage Bernard** - Director<BR>7. **Jayashree Vaidhyanthan** - Independent Director<BR>8. **RAJEEV KAKAR** - Independent Director<BR>9. **D K Mehrotra** - Chairman & Independent Director<BR>10. **ARVIND BHAGWAN DAS PATKAR** - Company Secretary & Compliance Officer<BR>11. **Kiran Kumar Tarania** - Nominee<BR>12. **Srivatsa Desikamani** - Nominee<BR><BR>This team comprises a mix of directors, independent directors, and nominees, overseeing the operations and governance of the company.

When is the next results date for UTI AMC?

No Upcoming Board Meetings

Has UTI AMC declared dividend?

Yes, UTI Asset Management Company Ltd has declared a 240% dividend, amounting to ₹24 per share, with an ex-date of July 18, 2024. The dividend yield is 3.96%, and total returns have shown strong performance over longer periods despite a recent decline.

UTI Asset Management Company Ltd has declared a 240% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 240%<BR>- Amount per share: 24 <BR>- Ex-date: 18 Jul 24<BR><BR>Dividend Yield: 3.96%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -7.18%, with a dividend return of 0%, resulting in a total return of -7.18%.<BR><BR>Over the past year, the price return was 28.15%, the dividend return was 2.44%, leading to a total return of 30.59%.<BR><BR>In the 2-year period, the price return was 68.05%, with a dividend return of 6.70%, culminating in a total return of 74.75%.<BR><BR>For the 3-year period, the price return was 86.97%, the dividend return was 10.74%, resulting in a total return of 97.71%.<BR><BR>In the last 4 years, the price return was 61.73%, with a dividend return of 9.68%, leading to a total return of 71.41%.<BR><BR>Over the past 5 years, the price return was 0%, with a dividend return of 0%, resulting in a total return of 0.0%.<BR><BR>Overall, UTI AMC has declared a significant dividend, and the total returns over various periods indicate strong performance, particularly in the longer terms, despite a recent downturn in the short term.

Who are the peers of the UTI AMC?

UTI AMC's peers include HDFC AMC, Motil.Oswal.Fin., Nippon Life Ind., 360 ONE, Prudent Corp, IIFL Capital, ICRA, CARE Ratings, and Share India Sec. In terms of performance, Share India Sec. leads with a 1-year return of 181.70%, while UTI AMC has a 1-year return of 24.36%.

Peers: The peers of UTI AMC are HDFC AMC, Motil.Oswal.Fin., Nippon Life Ind., 360 ONE, Prudent Corp, IIFL Capital, ICRA, CARE Ratings, and Share India Sec.<BR><BR>Quality Snapshot: Excellent management risk is observed at HDFC AMC, Nippon Life Ind., 360 ONE, and Prudent Corp, while Good management risk is found at Motil.Oswal.Fin., UTI AMC, ICRA, and CARE Ratings. Average management risk is present at IIFL Capital and Share India Sec. Growth is Excellent at Prudent Corp, while Average growth is noted at HDFC AMC, Nippon Life Ind., 360 ONE, and UTI AMC. Good growth is seen at Motil.Oswal.Fin. and IIFL Capital, while Below Average growth is reported at ICRA and CARE Ratings. Excellent capital structure is exhibited by HDFC AMC, Nippon Life Ind., 360 ONE, UTI AMC, Prudent Corp, IIFL Capital, ICRA, CARE Ratings, and Share India Sec.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Share India Sec. at 181.70%, while UTI AMC's 1-year return of 24.36% is lower than that. The peer with the lowest 1-year return is 360 ONE at 31.63%. Additionally, IIFL Capital, 360 ONE, and UTI AMC have negative six-month returns.

What does UTI AMC do?

UTI Asset Management Company Ltd manages private equity, venture funds, mutual funds, and portfolio management services for individual and institutional investors. As of March 2025, it reported net sales of ₹3,759 Cr and a net profit of ₹875 Cr, with a market cap of ₹18,404 Cr.

Overview: <BR>UTI Asset Management Company Ltd operates in the Capital Markets industry, focusing on managing private equity and venture funds, mutual funds, portfolio management services, and retirement solutions for both individual and institutional investors.<BR><BR>History: <BR>The company was incorporated on November 14, 2002, and later converted to a Public Limited company, officially changing its name to UTI Asset Management Company Limited on November 14, 2007. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3,759 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 875 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 18,404 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 25.00 <BR>Industry P/E: 23 <BR>Dividend Yield: 3.25% <BR>Debt Equity: 0.00 <BR>Return on Equity: 15.91% <BR>Price to Book: 4.00 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are the top shareholders of the UTI AMC?

The top shareholders of UTI AMC include T. Rowe Price International Ltd with 22.79%, 23 mutual fund schemes holding 13.14%, and 178 foreign institutional investors with 7.85%. Individual investors account for 7.44%, with no pledged promoter holdings reported.

The top shareholders of UTI AMC include T. Rowe Price International Ltd, which holds a significant 22.79% of the shares. Additionally, the company has 23 mutual fund schemes collectively holding 13.14% and 178 foreign institutional investors (FIIs) with a combined holding of 7.85%. Individual investors also account for 7.44% of the shareholding. Notably, there are no pledged promoter holdings and no specific promoter with the highest holding mentioned.

How big is UTI AMC?

As of 24th July, UTI Asset Management Company Ltd has a market capitalization of 18,300.00 Cr, with recent net sales of 1861.11 Cr and a net profit of 731.49 Cr.

As of 24th July, UTI Asset Management Company Ltd has a market capitalization of 18,300.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, UTI AMC reported Net Sales of 1861.11 Cr and a Net Profit of 731.49 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 4,599.13 Cr and Total Assets of 5,658.41 Cr.

Are UTI AMC latest results good or bad?

UTI AMC's latest results show strong quarterly growth with a 45.48% increase in net sales and a 170.81% rise in net profit, but year-on-year figures reveal only a 3.34% revenue increase and a 6.81% decline in net profit, indicating challenges in sustaining long-term growth and profitability.

UTI AMC's latest results present a mixed picture. On one hand, the company achieved a significant sequential improvement in net sales, which surged by 45.48% quarter-on-quarter to ₹546.89 crores. This recovery was primarily driven by performance-linked revenues. Additionally, net profit saw a remarkable increase of 170.81% QoQ, reaching ₹236.85 crores.<BR><BR>However, when looking at year-on-year performance, the results reveal some challenges. The revenue growth of just 3.34% YoY and a decline in net profit by 6.81% YoY indicate that the company is facing headwinds in sustaining its growth trajectory amidst a competitive market environment. Furthermore, the operating margin has compressed from previous highs, reflecting pressures on profitability.<BR><BR>Overall, while the quarterly performance shows strong recovery from the previous quarter, the year-on-year figures raise concerns about the company's ability to maintain growth and profitability in the long term. Investors should consider these factors when evaluating UTI AMC's performance.

Is UTI AMC overvalued or undervalued?

As of October 23, 2025, UTI AMC's stock is considered attractive and undervalued with a PE ratio of 28.68, significantly lower than peers like Bajaj Finance, and despite a year-to-date return of -1.86%, it has outperformed the Sensex over the last three years with a return of 73.81%.

As of 23 October 2025, the valuation grade for UTI AMC has moved from fair to attractive, indicating a more favorable assessment of the company's stock. The company is currently considered undervalued. Key ratios include a PE ratio of 28.68, an EV to EBITDA of 13.80, and a Price to Book Value of 0.38, which suggest that the stock is trading at a discount relative to its intrinsic value.<BR><BR>In comparison with peers, UTI AMC's PE ratio of 28.68 is significantly lower than that of Bajaj Finance at 39.07, which is categorized as very expensive, while Life Insurance, rated very attractive, has a PE of 11.68. The company's recent performance has been mixed, with a year-to-date return of -1.86% compared to the Sensex's 8.21%, but over the last three years, UTI AMC has outperformed the Sensex with a return of 73.81% versus 42.57%.

How has been the historical performance of UTI AMC?

UTI AMC has shown consistent growth in net sales and profits, with net sales rising from 1,266.86 Cr in March 2023 to 1,851.09 Cr in March 2025, and operating profit increasing to 1,110.42 Cr. However, earnings per share decreased slightly from 60.17 in March 2024 to 57.16 in March 2025, despite overall profit growth.

Answer:<BR>The historical performance of UTI AMC shows a consistent growth trend in net sales and profit over the years, with net sales reaching 1,851.09 Cr in March 2025, up from 1,736.96 Cr in March 2024 and significantly higher than 1,266.86 Cr in March 2023. Operating profit (PBDIT) also increased to 1,110.42 Cr in March 2025 from 1,040.37 Cr in March 2024, indicating improved operational efficiency. Profit before tax rose to 1,052.17 Cr in March 2025, compared to 986.84 Cr in the previous year, while profit after tax was 812.96 Cr, slightly up from 802.03 Cr in March 2024. The company's earnings per share (EPS) decreased to 57.16 in March 2025 from 60.17 in March 2024, reflecting a slight decline in profitability per share despite the overall profit growth. <BR><BR>Breakdown:<BR>Over the years, UTI AMC has demonstrated a robust growth trajectory in its financial performance. From March 2020 to March 2025, net sales have increased from 854.03 Cr to 1,851.09 Cr, showcasing a strong upward trend. Operating profit has also seen a significant rise, moving from 348.31 Cr in March 2020 to 1,110.42 Cr in March 2025, indicating enhanced operational efficiency. Profit before tax has followed suit, climbing from 341.30 Cr in March 2020 to 1,052.17 Cr in March 2025. However, the profit after tax has shown a more modest increase, reaching 812.96 Cr in March 2025, up from 802.03 Cr in March 2024. The company's earnings per share peaked in March 2024 at 60.17 but fell to 57.16 in March 2025. Overall, UTI AMC's financial metrics reflect a solid performance with increasing revenues and profits, despite some fluctuations in profitability per share.

Should I buy, sell or hold UTI AMC?

Is UTI AMC technically bullish or bearish?

As of November 19, 2025, the technical trend is mildly bearish, indicated by bearish signals from MACD, Bollinger Bands, KST, and OBV across weekly and monthly time frames, despite a mildly bullish daily moving average.

As of 19 November 2025, the technical trend has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven by several key indicators. The MACD is mildly bearish on both the weekly and monthly time frames, while Bollinger Bands also indicate a bearish trend on both time frames. The KST and OBV are both mildly bearish weekly and monthly as well. Although the daily moving averages show a mildly bullish signal, the overall sentiment remains bearish due to the prevailing trends in the longer time frames. The stock has underperformed compared to the Sensex over the past month and year, further supporting the bearish outlook.

Which are the latest news on UTI AMC?

Why is UTI AMC falling/rising?

As of 03-Dec, UTI Asset Management Company Ltd's stock price is at 1,131.25, reflecting a decline of 1.63%. The stock has significantly underperformed the benchmark Sensex, with a year-to-date drop of 15.58% compared to the Sensex's gain of 8.92%, driven by poor financial results and a bearish trend indicated by trading below moving averages.

As of 03-Dec, UTI Asset Management Company Ltd's stock price is falling, currently at 1,131.25, which reflects a decrease of 18.7 points or 1.63%. The stock has been underperforming compared to the benchmark Sensex, with a decline of 2.06% over the past week, and a significant drop of 8.53% over the past month, while the Sensex has gained 1.34% in the same period. Year-to-date, the stock has fallen by 15.58%, contrasting sharply with the Sensex's gain of 8.92%.<BR><BR>Today's performance indicates that the stock has underperformed its sector by 0.57%, and it has experienced consecutive declines over the last two days, totaling a drop of 1.77%. The stock reached an intraday low of Rs 1126.5, marking a 2.04% decrease. Furthermore, UTI AMC is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bearish trend.<BR><BR>The company's recent financial results have also contributed to the stock's decline. In the latest quarter, the profit before tax fell by 37.4%, net profit decreased by 36.7%, and net sales dropped by 10.9% compared to the previous four-quarter average. This negative performance has led to a significant underperformance relative to the broader market, where the BSE500 index has generated positive returns of 2.66% over the past year, while UTI AMC has seen a decline of 13.73%.<BR><BR>Despite a high dividend yield of 4.15% and strong long-term fundamentals, including a return on equity of 15.72%, the recent poor financial results and the stock's consistent underperformance against both the market and its peers have resulted in a downward trend in its price.